dr. agarwal discusses results of keynote-426 in mrcc
Published 5 years ago • 207 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:59
dr rini on the background of a biomarker analysis of keynote-426 in rcc
-
9:05
drs. rini, wallis on a 5-year analysis of keynote-426 for advanced clear cell rcc
-
1:33
dr. powles on the results of the keynote-426 trial in mrcc
-
1:18
dr rini on a biomarker analysis of keynote-426 using subtype clustering rcc
-
4:56
dr. rini discusses asco 2023 data in frontline rcc: clear and keynote-426 trials
-
6:52
endonasal dcr and septoplasty | mr. abdul khaliq | kenya | dr. kvssrk sastry | yashoda hospitals
-
8:08
dr. k. k. aggarwal - healthy funda
-
42:21
unlock the secrets to happy eyes in a digital world
-
1:15
dr. plimack on updated findings of the keynote-426 study in rcc
-
6:58
keynote-426 study
-
2:18
dr. agarwal on frontline treatment in kidney cancer
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
1:34
dr. powles on rationale for keynote-426 in mrcc
-
1:31
dr. agarwal on the combination of lenvatinib and everolimus in mrcc
-
2:16
updated results from keynote-426 for metastatic kidney cancer
-
0:53
dr. agarwal on emerging immunotherapeutic combinations in kidney cancer
-
1:54
dr. agarwal on developing biomarkers of response to cabozantinib/atezolizumab in mcrpc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
0:22
copy of dr. agarwal on second-line therapy selection in metastatic rcc
-
0:49
dr. agarwal on remaining questions with renal cell carcinoma
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc